What do systematic reviews say?

PDEI plus alpha‐blocker vs alpha‐blocker

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 193 participants
  Low

PDEI plus alpha‐blocker vs alpha‐blocker

The review found no eligible studies for this question.

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

PDEI plus alpha‐blocker vs alpha‐blocker

PDEI plus alpha‐blocker probably leads to higher adverse effects compared with alpha‐blockers alone (moderate certainty).

• Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 2.81 [1.53, 5.17]
  4 studies · 194 participants
  Moderate